Pocivavsek A, Schwarcz R, Erhardt S
Pharmacol Rev. 2024; 76(6):978-1008.
PMID: 39304346
PMC: 11549936.
DOI: 10.1124/pharmrev.124.000239.
Chan B, Lynch N, Tran W, Joyce J, Savage G, Meutermans W
Front Chem. 2024; 12:1379518.
PMID: 38698940
PMC: 11063241.
DOI: 10.3389/fchem.2024.1379518.
Rentschler K, Milosavljevic S, Baratta A, Wright C, Piroli M, Tentor Z
J Sleep Res. 2023; 33(3):e14038.
PMID: 37678806
PMC: 10918043.
DOI: 10.1111/jsr.14038.
Maryska M, Svobodova L, Dehaen W, Hrabinova M, Rumlova M, Soukup O
Pharmaceuticals (Basel). 2021; 14(12).
PMID: 34959692
PMC: 8708382.
DOI: 10.3390/ph14121291.
Zador F, Nagy-Grocz G, Kekesi G, Dvoracsko S, Szucs E, Tomboly C
Molecules. 2019; 24(20).
PMID: 31619006
PMC: 6832375.
DOI: 10.3390/molecules24203709.
Selective and competitive inhibition of kynurenine aminotransferase 2 by glycyrrhizic acid and its analogues.
Yoshida Y, Fujigaki H, Kato K, Yamazaki K, Fujigaki S, Kunisawa K
Sci Rep. 2019; 9(1):10243.
PMID: 31308447
PMC: 6629613.
DOI: 10.1038/s41598-019-46666-y.
Improvement of kynurenine aminotransferase-II inhibitors guided by mimicking sulfate esters.
Jayawickrama G, Nematollahi A, Sun G, Church W
PLoS One. 2018; 13(4):e0196404.
PMID: 29689093
PMC: 5915280.
DOI: 10.1371/journal.pone.0196404.
Inhibition of human kynurenine aminotransferase isozymes by estrogen and its derivatives.
Jayawickrama G, Nematollahi A, Sun G, Gorrell M, Church W
Sci Rep. 2017; 7(1):17559.
PMID: 29242525
PMC: 5730616.
DOI: 10.1038/s41598-017-17979-7.
Major Developments in the Design of Inhibitors along the Kynurenine Pathway.
Jacobs K, Castellano-Gonzalez G, Guillemin G, Lovejoy D
Curr Med Chem. 2017; 24(23):2471-2495.
PMID: 28464785
PMC: 5748880.
DOI: 10.2174/0929867324666170502123114.
Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.
Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung J, Gerretsen P
Schizophr Bull. 2017; 43(4):764-777.
PMID: 28187219
PMC: 5472151.
DOI: 10.1093/schbul/sbw221.
Kynurenine Aminotransferase Isozyme Inhibitors: A Review.
Nematollahi A, Sun G, Jayawickrama G, Church W
Int J Mol Sci. 2016; 17(6).
PMID: 27314340
PMC: 4926479.
DOI: 10.3390/ijms17060946.
Kynurenines and Glutamate: Multiple Links and Therapeutic Implications.
Schwarcz R
Adv Pharmacol. 2016; 76:13-37.
PMID: 27288072
PMC: 5803753.
DOI: 10.1016/bs.apha.2016.01.005.
Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior.
Notarangelo F, Pocivavsek A
Neuropharmacology. 2016; 112(Pt B):275-285.
PMID: 26944732
PMC: 5010529.
DOI: 10.1016/j.neuropharm.2016.03.001.
Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions.
Tuttle J, Anderson M, Bechle B, Campbell B, Chang C, Dounay A
ACS Med Chem Lett. 2014; 4(1):37-40.
PMID: 24900560
PMC: 4027135.
DOI: 10.1021/ml300237v.
Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia.
Dounay A, Anderson M, Bechle B, Campbell B, Claffey M, Evdokimov A
ACS Med Chem Lett. 2014; 3(3):187-92.
PMID: 24900455
PMC: 4025856.
DOI: 10.1021/ml200204m.
Kynurenines with neuroactive and redox properties: relevance to aging and brain diseases.
Reyes Ocampo J, Lugo Huitron R, Gonzalez-Esquivel D, Ugalde-Muniz P, Jimenez-Anguiano A, Pineda B
Oxid Med Cell Longev. 2014; 2014:646909.
PMID: 24693337
PMC: 3945746.
DOI: 10.1155/2014/646909.
A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats.
Cherian A, Gritton H, Johnson D, Young D, Kozak R, Sarter M
Neuropharmacology. 2014; 82:41-8.
PMID: 24647121
PMC: 4372264.
DOI: 10.1016/j.neuropharm.2014.03.004.
Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor.
Wu H, Okuyama M, Kajii Y, Pocivavsek A, Bruno J, Schwarcz R
Schizophr Bull. 2014; 40 Suppl 2:S152-8.
PMID: 24562494
PMC: 3934402.
DOI: 10.1093/schbul/sbt157.
Eimeria falciformis infection of the mouse caecum identifies opposing roles of IFNγ-regulated host pathways for the parasite development.
Schmid M, Heitlinger E, Spork S, Mollenkopf H, Lucius R, Gupta N
Mucosal Immunol. 2013; 7(4):969-82.
PMID: 24368565
DOI: 10.1038/mi.2013.115.
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.
Stone T, Darlington L
Br J Pharmacol. 2013; 169(6):1211-27.
PMID: 23647169
PMC: 3831703.
DOI: 10.1111/bph.12230.
